Connection
Michael Johnson to Vaccines, Synthetic
This is a "connection" page, showing publications Michael Johnson has written about Vaccines, Synthetic.
|
|
Connection Strength |
|
 |
|
 |
|
0.339 |
|
|
|
-
Johnson MJ, Liu C, Ghosh D, Lang N, Levin MJ, Weinberg A. Cell-Mediated Immune Responses After Administration of the Live or the Recombinant Zoster Vaccine: 5-Year Persistence. J Infect Dis. 2022 04 19; 225(8):1477-1481.
Score: 0.193
-
Laing KJ, Ford ES, Johnson MJ, Levin MJ, Koelle DM, Weinberg A. Recruitment of naive CD4+ T cells by the recombinant zoster vaccine correlates with persistent immunity. J Clin Invest. 2023 12 01; 133(23).
Score: 0.054
-
Weinberg A, Scott Schmid D, Leung J, Johnson MJ, Miao C, Levin MJ. Predictors of 5-Year Persistence of Antibody Responses to Zoster Vaccines. J Infect Dis. 2023 11 11; 228(10):1367-1374.
Score: 0.054
-
Levin MJ, Kroehl ME, Johnson MJ, Hammes A, Reinhold D, Lang N, Weinberg A. Th1 memory differentiates recombinant from live herpes zoster vaccines. J Clin Invest. 2018 10 01; 128(10):4429-4440.
Score: 0.037
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|